Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.
Conditions: Colorectal Neoplasms; Microbiota; Prognosis; Metabolic Syndrome; Sarcopenia Intervention: Other: no intervention Sponsors: University Hospital, Clermont-Ferrand; M2iSH laboratory; Benoit Chassaing Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer & Oncology | Eating Disorders & Weight Management | Hospitals | Laboratory Medicine | Metabolic Syndrome | Obesity | Research